Physician profile
Huma Khusro
NPI 1104929587
$5,571.81
in general payments reported to CMS, 2019-2025
20 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $929 · 2021: $878 · 2022: $1,375 · 2023: $1,035 · 2024: $92.57 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,130.99 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $585.22 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $562.49 | 2019-2025 | Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $509.70 | 2021-2024 | Caplyta |
| Bausch Health US, LLC | $484.29 | 2019-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $443.90 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $424.11 | 2020-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $361.81 | 2019-2022 | |
| Abbvie INC. | $348.75 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.53 | 2019-2023 | Trintellix |
| Indivior INC. | $139.23 | 2021-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $90.72 | 2025 | Cobenfy |
| Lundbeck LLC | $78.83 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $76.03 | 2019-2020 | |
| Axsome Therapeutics, INC. | $47.74 | 2023 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.57 | 2020 | |
| Corium, LLC | $21.10 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $13.91 | 2020 | |
| Eisai INC. | $12.65 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Khusro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.